Myeloperoxidase enzyme levels and oxidative stress in bipolar disorders

African Journal of Biotechnology

Volumn 9, Issue 22, 2010, Pages 3318-3323

  Nur Aksoy, S ^a   Saygili, Eyup Ilker ^a   Bulbul, Feridun ^b   Bahar, Aynur ^a   Savas, Haluk ^a   Virit, Osman ^a   Altindag, Abdurrahman ^a   Bayram, Aysen ^a   Tarakçioǧlu, Mehmet ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Nizip State Hospital   (Turkey)

Author keywords

ADHD; Bipolar disorder; CRP; MDA; Myeloperoxidase

Indexed keywords

C REACTIVE PROTEIN; MALONALDEHYDE; MYELOPEROXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGE; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BLOOD ANALYSIS; BODY HEIGHT; BODY WEIGHT; CIGARETTE SMOKING; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; FAMILY HISTORY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MANIA; NEPHELOMETRY; OXIDATIVE STRESS; SPECTROPHOTOMETRY;

EID: 77953525382     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A (2007). Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo.18: 377-390.
2. Akyol O, Herken H, Uz E, Fadillioǧlu E, Unal S, Söǧüt S, Ozyurt H, Savaş HA (2002). The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharm. Biol. Psychiatry, 26: 995-1005.
3. Altuntas I, Aksoy H, Coskun I, Cayköylü A, Akcay F (2000). Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab. Med. 38: 1277-1281.
4. American Psychiatric Association (APA) (2000). Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision.Washington, DC.: American Psychiatric Association Press.
5. American Academy of Child and Adolescent Psychiatry (AACAP) (2007). Practice parameter for the assessment and treatment of children and adolescent with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry, 46(7): 894-921.
6. Andreazza AC, Cassini C, Rosa AR, Leite MC, Almeida LM, Nardin P, Cunha AB, Cereser KM, Santin, Gottfried C, Salvador M, Kapczinski F, Gonçalves CA (2007). Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatry Res. 41: 523-529.
7. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ (2003). Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349: 1595-1604.
8. Bulut M, Selek S, Gergerlioglu HS, Savas HA, Yilmaz HR, Yuce M, Ekici G (2007). Malondialdehyde levels in adult attention deficit/hyperactivity disorder. J. Psychiatry Neurosci. 32: 435-438.
9. Carney RM, Freedland KE, Miller GE, Jaffe AS (2002) Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms. J. Psychosom. Res. 53: 897-902.
10. Casado A, Encarnación López-Fernández M, Concepción Casado M, de La Torre R (2008). Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem. Res. 33(3): 450-458.
11. Douglas KM, Taylor AJ, O'Malley PG (2004). Relationship between depression and C reactive protein in a screening population. Psychosom. Med. 66: 679-683.
12. Elliott H (2002). Attention deficit hyperactivity disorder in adults: a guide for the primary care physician. South Med. J. 95(7): 736-742.
13. Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiler D, Ferrieres J (2005). Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circ. 111: 2299-2305.
14. Gergerlioǧlu HS, Savas HA, Bulbul F, Selek S, Uz E, Yumru M (2007). Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31: 697-702.
15. Graham DB, Robertson CM, Bautista J, Mascarenhas F, Diacovo JM, Montgrain V, Siu Lam SK, Cremasco V, Dunne WM, Faccio R, Coopersmith CM, Swat W (2007). Neutrophil-mediated oxidative burst and host defense are controlled by a Vav-PLCγ2 signaling axis in mice. J. Clin. Invest. 117(11): 3445-3452.
16. Faith M, Sukumaran A, Pulimood AB, Jacob M (2008). How reliable an indicator of inflammation is myeloperoxidase activity?. Clinica Chimica Acta. 396(1-2): 23-25.
17. Haegens A, Vernooy JH, Heeringa P, Mossman BT, Wouters EF (2008). Myeloperoxidase modulates lung epithelial responses to proinflammatory agents. Eur. Respir. J. 31: 252-260.
18. Halliwell B, Gutteridge JMC (2000). Free Radicals in Biology and Medicine. Third edition. Oxford Science Publications, New York, Oxford University Press.
19. Hampton MB, Ketle AJ, Winterbourn CC (1998). Inside the neutrophil phagosome: oxidants, myeloperoxidase and bacterial killing. Blood. 92(9): 3007-3017.
20. Harrison JE, Schultz J (1976). Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem. 251: 1371-1374.
21. Huang TL, Lin FC (2007). High-sensitivity C-reactive protein levels in patients with major dpressive disorder and bipolar mania. Prog. Neuropsychopharm. Biol. Psychiatry, 31(2): 370-372.
22. Jain SK, McVie R, Duett J, Herbst JJ (1989). Erythrocyte membrane lipid peroxidation and glycocylated hemoglobin in diabetes. Diabetes, 38: 1539-1543.
23. Ji KA, Yang MS, Jeong HK, Min KJ, Kang SH, Jou I, Joe EH (2007). Resident microglia die and infiltrated neutrophils and monocytes become major inflammatory cells in lipopolysaccharide-injected brain. Glia. 55(15): 1577-1588.
24. Lowe GD (2005). Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J. Thromb. Haemost. 3: 1618-1627.
25. Klebanoff SJ (1999). Myeloperoxidase. Proc. Assoc. Am. Phys. 111: 383-389.
26. Kuloglu M, Atmaca M, Tezcan E, Ustundag B, Bulut S (2002). Antioxidant enzyme activities and malondialdehyde levels in patients with obsessivecompulsive disorder. Neuropsychobiol. 46: 27-32.
27. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser JrV, da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V (2007). Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421: 33-36.
28. Mahadik SP, Mukherjee S (1996). Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophrenia Res. 19: 1-17.
29. Mander PK, Jekabsone A, Brown GC (2006). Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. J. Immunol. 176: 1046-1052.
30. Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, Reynolds WF (1997). Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J. Neuroimmunol. 78(1-2): 97-107.
31. Ng F, Berk M, Dean O, Bush AI (2008). Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 11(6): 851-76.
32. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004). Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 19: 89-95.
33. Piao MJ, Kang KA, Zhang R, Ko DO, Wang ZH, You HJ, Kim HS, Kim JS, Kang SS, Hyun JW (2008). Hyperoside prevents oxidative damage induced by hydrogen peroxide in lung fibroblast cells via an antioxidant effect. Biochim. Biophys. Acta. 1780(12): 1448-1457.
34. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP (2003). Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 121(2): 109-122.
35. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E (1999). Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp. Neurol. 155: 31-41.
36. Ridker P (2003). Clinical application for C-reactive protein for vascular disease detection and prevention. Circulation. 107: 363-369.
37. Sanyal J, Bandyopadhyay SK, Banerjee TK, Mukherjee SC, Chakraborty DP, Ray BC, Rao VR (2009). Plasma levels of lipid peroxides in patients with Parkinson's disease. Eur. Rev. Med. Pharmacol. Sci. 13(2): 129-132.
38. Sorce S, Krause KH (2009). NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal. 23: 131-135.
39. Trantham-Davidson H, Vazdarjanova A, Dai R, Terry A, Bergson C (2008). Up-regulation of calcyon results in locomotor hyperactivity and reduced anxiety in mice. Behav. Brain Res. 189(2): 244-249.
40. Ulvestad E, Williams K, Mork S, Antel J, Nyland H (1994). Phenotypic differences between human monocytes/macrophages and microglial cells studied in situ and in vitro. J. Neuropathol. Exp. Neurol. 53: 492-501.
41. Vaccarino V, Brennan ML, Miller AH, Bremner JD, Ritchie JC, Lindau F, Veledar E, Su S, Murrah NV, Jones L, Jawed F, Dai J, Goldberg J, Hazen SL (2008). Association of Major Depressive Disorder with Serum Myeloperoxidase and other Markers of Inflammation: A Twin Study. Biol. Psychiatry, 64(6): 476-483.
42. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M (2002). Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 17: 175-179.
43. Winterbourn CC, Kettle AJ (2004). Reactions of superoxide with myeloperoxidase and its products. Jpn. J. Infect. Dis. 57(5): 31-33.
44. Yap YW, Whiteman M, Cheung NS (2007). Chlorinative stress: an under appreciated mediator of neurodegeneration? Cell. Signal. 19: 219-228.
45. Zepf FD (2009). Attention deficit-hyperactivity disorder and early-onset bipolar disorder: two facets of one entity? Dial. Clin. Neurosci. 11(1): 63-72.